Prevalence, Comorbidities, and Risk Factors of Erectile Dysfunction: Results from a Prospective Real-World Study in the United Kingdom

Table 4

Pharmacological treatments for underlying cardiometabolic and psychological comorbidities in men with ED and men without ED.

Medications	ED status		Two-sided p value
	ED (n = 5,185)	No ED (n = 7,305)
Alpha blocker-heart conditions, n (%)	300 (5.8)	108 (1.5)	<0.001
Antidepressants, n (%)	891 (17.2)	719 (9.8)	<0.001
Blood pressure medication, n (%)	1,677 (32.3)	1,034 (14.2)	<0.001
Statins, n (%)	1,479 (28.5)	845 (11.6)	<0.001
Diabetes medication, n (%)	712 (13.7)	355 (4.9)	<0.001
Nitrates, n (%)	170 (3.3)	46 (0.6)	<0.001
Vasodilators, n (%)	114 (2.2)	28 (0.4)	<0.001
≥1 of the above, n (%)	2,836 (54.7)	2,047 (28.0)	<0.001

ED, erectile dysfunction.